Mapping Evidence on the Burden of Breast, Cervical, and Prostate Cancers in Sub-Saharan Africa: A Scoping Review

Alfred Musekiwa*, Maureen Moyo1, Mohanad Mohammed2, Zvifadzo Matsena-Zingoni3, Halima Sumayya Twabi*, Jesca Mercy Batidzirai2, Geoffrey Chiyuzga Singini4, Kabelo Kgarosi1, Nobuhle Mchunu2,6, Portia Nevhungoni2,6, Patricia Silinda1, Theodora Ekwomadu7 and Innocent Maposa3

1 School of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa, 2 School of Mathematics, Statistics, and Computer Science, University of KwaZulu-Natal, Pietermaritzburg, South Africa, 3 Division of Epidemiology and Biostatistics, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa, 4 Department of Mathematical Sciences, University of Malawi, Zomba, Malawi, 5 Biostatistics Unit, South African Medical Research Council, Durban, South Africa, 6 Biostatistics Unit, South African Medical Research Council, Pretoria, South Africa, 7 Department of Biological Sciences, Faculty of Natural and Agricultural Sciences, North-West University, Mmabatho, South Africa

Background: Cancer remains a major public health problem, especially in Sub-Saharan Africa (SSA) where the provision of health care is poor. This scoping review mapped evidence in the literature regarding the burden of cervical, breast and prostate cancers in SSA.

Methods: We conducted this scoping review using the Arksey and O’Malley framework, with five steps: identifying the research question; searching for relevant studies; selecting studies; charting the data; and collating, summarizing, and reporting the data. We performed all the steps independently and resolved disagreements through discussion. We used Endnote software to manage references and the Rayyan software to screen studies.

Results: We found 138 studies that met our inclusion criteria from 2,751 studies identified through the electronic databases. The majority were retrospective studies of mostly registries and patient files ($n = 77, 55.8\%$), followed by cross-sectional studies ($n = 51, 36.9\%$). We included studies published from 1990 to 2021, with a sharp increase from 2010 to 2021. The quality of studies was overall satisfactory. Most studies were done in South Africa ($n = 20$) and Nigeria ($n = 17$). The majority were on cervical cancer ($n = 93, 67.4\%$), followed by breast cancer (67, 48.6\%) and the least were on prostate cancer (48, 34.8\%). Concerning the burden of cancer, most reported prevalence and incidence. We also found a few studies investigating mortality, disability-adjusted life years (DALYs), and years of life lost (YLL).

Conclusions: We found many retrospective record review cross-sectional studies, mainly in South Africa and Nigeria, reporting the prevalence and incidence of cervical,
INTRODUCTION

The burden of cancer is on a rise in developing countries due to the demographic transitions and changes in life-style behaviors (1–4). The most common cancer cases among women in Sub-Saharan Africa (SSA) are breast (25% of all cancers) and cervical (24% of all cancers), while prostate cancer (23% of all cancers) is common among men in SSA (5, 6). Of all the 2018 cancer deaths among women in SSA, 21.7% were attributed to cervical cancer, making it the most common cause of cancer death in the region (7). Breast cancer mortality is high in SSA compared to developed countries (8–13). The prevalence of prostate cancer among men has been high in SSA as it is the leading cause of cancer deaths, particularly among men of African origins (14).

Determining the burden of prostate cancer within SSA has been challenging due to the lack of reliable reporting. The incidence of breast cancer has been reported to be higher in rural areas (60–75%) than in urban areas in SSA (15), and many of these women go untreated, mostly due to a lack of access to health care. One study found that prostate cancer is a serious challenge in African men and its actual incidence is underestimated in SSA settings due to poor access to healthcare, lack of screening, genetic predisposition, lifestyle and environmental factors (4). According to Jalloh et al. (16), most of the health interventions in SSA have focused on communicable diseases such as malaria, tuberculosis and HIV, however, cancer care has been given limited attention.

This study aims to determine recent trends in the burden, including incidence, prevalence, and disability-adjusted life years (DALYs), of breast, cervical and prostate cancer in SSA. Highlighting the burden of the three most common cancers helps bring disparate information reported in the literature to policy makers in an easy and accessible format, in one place. The focus is on SSA because this is where early marriages are rampant and hence girls younger than 15 years old are exposed to early sexual activity, thus increasing their risk of contracting Human Papilloma Virus (HPV), a risk factor for cervical cancer, at a young age (17). In addition, evidence has shown that cervical cancer is more prevalent in HIV-infected women compared to the HIV-uninfected, and their survival rates are poorer (18). Furthermore, breast and prostate cancer awareness and treatment are lower in SSA due to limited resources. This scoping review seeks to provide evidence on the burden of these three most common types of cancers in SSA. Results from this study will add to the body of literature and help policy makers in making informed decisions that will improve the public health systems in reducing the cancer burden in SSA.

METHODS

Study Design

This scoping review aimed to collate, synthesize, and analyze the wide range of available evidence to map literature on the burden of breast, cervical and prostate cancers in SSA. The title was registered with the Open Science Framework (OSF) (https://archive.org/details/osf-registrations-bna26-v1). The scoping review used the Arksey and O’Malley framework (19) as reviewed and updated by Levac et al. (20) and the Joanna Briggs Institute 2020 guidelines (21). The framework has the following five steps that guide how scoping reviews are done:

- Step 1: Identifying the research question.
- Step 2: Identifying relevant studies.
- Step 3: Selecting studies.
- Step 4: Charting the data.
- Step 5: Collating, summarizing and reporting the data.

The scoping review was reported using the Preferred Reporting Items for Systematic Reviews and Meta-analysis: Extension for Scoping Reviews (PRISMA-ScR) guidelines (22).

Identifying the Research Question

Our primary research question for the scoping review was: What evidence exists on the epidemiological burden of breast, cervical and prostate cancers in SSA? The measures of burden include spatial distribution, incidence, prevalence, quality-adjusted life years (QALYs), disability-adjusted life years (DALYs), and years of life lost (YLL).

To assess the eligibility of the research question, this scoping review utilized the Population, Concept and Context (PCC) mnemonic, derived by the Joanna Briggs Institute (21). The PCC statement guided the selection of studies (Table 1).

**TABLE 1 |** PCC framework used to determine the eligibility of the research question and to guide the selection of studies on the burden of breast, cervical and prostate cancers.

| Population | Adult cancer patients (breast, cervical, prostate) |
|------------|-----------------------------------------------|
| Concept    | Burden of breast, cervical, and prostate cancer |
| Context    | Sub-Saharan Africa                            |

**Abbreviations:** MeSH, Medical Subject Headings; MMAT, Mixed Methods Appraisal Tool; PHC, Primary Healthcare; PRISMA-ScR, Preferred Reporting Items for Systematic Reviews and Meta-analysis: Extension for Scoping Reviews; UN, United Nations; WHO, World Health Organization.

Keywords: breast cancer, cervical cancer, prostate cancer, burden, Sub-Saharan Africa
Identifying Relevant Studies

We conducted a comprehensive search from inception to 25 October 2021, irrespective of language, in the following electronic databases: PubMed, Web of Science, and Scopus. The search strategy was developed with an experienced librarian (KK, who is also the co-author) using a variety of keywords related to the burden of breast, cervical and prostate cancers in SSA. A combination of these keywords and Medical Subject Heading (MeSH) terms were used and tailored appropriately to each database. In addition, we manually searched the reference lists of all included studies to identify additional literature. Table 2 shows a pilot search strategy used in PubMed. The actual search strategies used are given in the Supplementary Materials.

**Eligibility Criteria**

We conducted an extensive title and abstract screening guided by the study’s eligibility criteria to determine all eligible articles to be selected for this scoping review. To account for all eligible studies included in the review, the inclusion and exclusion criteria listed below were followed.

**Inclusion Criteria**

This study included all publications that adhered to the following criteria:

- Studies reporting on at least one of the types of cancers, that is, breast, cervical and prostate.
- Studies reporting on the burden (prevalence, incidence, QALYs, DALYs, and others) on at least one of breast, cervical and prostate cancers.
- All publications reporting evidence on the three cancers in different SSA countries; this was not limited by study design.
- Studies from all countries in SSA (all countries in Africa except Algeria, Egypt, Morocco, Tunisia, and Libya).

**Exclusion Criteria**

This review excluded studies based on the following:

- Any articles reporting on cancers other than cervical, breast and prostate cancers
- Northern African countries (Algeria, Egypt, Morocco, Tunisia, and Libya) which are not considered SSA.

**Selecting Studies**

We screened the titles of the associated selected articles from the different repositories. After that, we used EndNote 20 software to identify the duplicates in the qualified articles and deleted them. The abstracts of the qualified articles were examined by two independent reviewers using a screening tool that specifies inclusion and exclusion criteria. In this stage, the reviewers resolved any contradiction by involving a third reviewer. The two reviewers then explored the full text of the selected articles using the screening tool. After this phase, any contradictions arising were resolved independently by a third reviewer. For any articles that could not be accessed during the screening phase, the librarian assisted in retrieving the full-text articles. The database searches, keywords used, and the number of selected articles were properly reported. Also, the screening results were displayed using a PRISMA-ScR flow diagram (22).

**Charting the Data**

To extract relevant information from each of the selected articles, an electronic data charting form was developed with data extraction tool components, including author and date, title, country, study design, type of cancer (cervical, breast, prostate), type of burden reported, and key findings. The data extraction tool was piloted by two independent reviewers before use. Any appropriate changes were then applied as per the feedback received during the piloting stage and the tool was updated accordingly.

**Quality Appraisal**

We used the Mixed Methods Appraisal Tool (MMAT) V.2018 software (23) to assess the quality of studies since we anticipated different types of study designs to be included in the scoping review. The tool included the relevance of the study, the study design, adequacy and methodology, data collection, data analysis and the main study findings. The process of quality appraisal was performed independently and in duplicate by at least two review authors to avoid any bias. Disagreements between reviewers were resolved through discussion.

**Collating, Summarizing and Reporting Results**

We summarized the emerging themes for the burden of the three cancers using a narrative approach. The summary was structured around the burden and types of cancers. We also meticulously analyzed and reported any other emerging themes relevant to the research question. Where appropriate we used tables and graphs to visualize findings. The results of this scoping review were used to determine the gaps in knowledge regarding the burden of breast, cervical and prostate cancer in SSA.
**FIGURE 1** | PRISMA flow chart showing the number of studies included in a scoping review for breast, cervical, and prostate cancer in Sub-Saharan Africa.

**FIGURE 2** | Pie chart showing study designs for studies on breast, cervical, and prostate cancer in Sub-Saharan Africa.
The majority of the included studies were retrospective studies (n = 77, 55.8%) of mostly registries and patient files (6, 10, 24–98) followed by cross-sectional studies (n = 51, 36.9%) (99–149), systematic reviews (n = 5, 3.6%) (2, 150–153) and reviews (n = 2, 2.1%) (154, 155). There were two prospective studies (156, 157) and one modeling study (158) (Figure 2).

The prevalence studies had different target populations, with some only targeting cancer patients and calculating the percentage of each type of cancer. Some cross-sectional studies were targeting the general population, including screening studies.

Year of Publication
We included studies published from 1990 to 2021 (Figure 3).

FIGURE 3 | Trend in the number of included studies over time in years, 1990 to 2021.

RESULTS

Results of the Search
A total of 2,751 studies were found in three electronic databases (PubMed, Web of Science, and Scopus). After removing 1,077 duplicate records, we remained with 1,674 records whose titles and abstracts were screened. Screening resulted in 1,487 records being excluded for being irrelevant, thus leaving 187 reports that were sought to have their full texts retrieved, however, five records could not be retrieved, and this resulted in 182 full-text reports that were assessed for eligibility by at least two reviewers. Finally, 44 records were excluded after the full-text screening, reports that were assessed for eligibility by at least two reviewers.

Characteristics of Included Studies

Study Designs and Quality of Included Studies

Study Designs
The quality of studies, assessed using the Mixed Methods Assessment Tool (MMAT), is summarized in Table 3. The assessment excludes the five systematic reviews, two reviews, and the modeling study. Therefore, the assessment was carried out for 130 studies; the majority were quantitative studies (n = 129) and they satisfied all the qualities in the table; appropriate sampling strategy, representative sample, appropriate measurements, low nonresponse bias, and using appropriate statistical methods. There was one mixed-methods study (133), which had an adequate rationale for mixed methods and had both the quantitative and qualitative aspects adequately interpreted.

Spatial Distribution of Studies
While most studies were single-country studies, some were multi-country and global studies including African countries. There were 16 global studies including the African or SSA regions (27, 46, 69, 104, 106, 108, 109, 117, 121, 122, 127, 131, 142, 144, 145, 158) and there were 16 African multi-country studies (2, 6, 87, 119, 120, 138, 140, 141, 143, 148–154). From the single-country studies, majority were done in Nigeria (n = 17) (24, 25, 28, 29, 34, 45, 54, 64, 72, 75, 92, 93, 103, 113, 116, 124, 137) and South Africa (n = 20) (10, 26, 36, 42, 55, 65, 80–83, 86, 88, 89, 91, 98, 105, 110, 125, 129, 135), followed by Uganda (n = 10) (35, 40, 48, 59, 74, 78, 79, 90, 94, 95), then Malawi (n = 9) (37, 52, 53, 56, 66–68, 118, 133) and Ethiopia (n = 9) (33, 51, 63, 97, 101, 107, 112, 146, 157). We also found studies conducted in Ghana (n = 6) (50, 71, 111, 123, 134, 155), Kenya (n = 5) (70, 96, 115, 132, 139), Zambia (n = 4) (44, 77, 102, 126), and Eritrea (n = 3) (60–62). There were seven countries with two studies each [Botswana (43, 47), the Central African Republic (31, 32), Mozambique (57, 58), Rwanda (130, 136), Senegal (147, 156), Sudan (84, 114) and Zimbabwe (38, 39)]. The countries

Quality of Studies (MMAT Tool)

Spatial Distribution of Studies
TABLE 3 | MMAT table for Sub-Saharan African studies on the burden of cervical, breast and prostate cancer.

| Study type | Question | Yes | No | Cannot tell | Total |
|------------|----------|-----|----|-------------|-------|
| SCREENING QUESTIONS | S1. Are there clear research questions? | 128 | 0 | 2 | 130 |
| | S2. Do the collected data allow us to address the research questions? | 129 | 0 | 1 | 130 |
| QUANTITATIVE DESCRIPTIVE STUDIES | 4.1. Is the sampling strategy relevant in addressing the research question? | 127 | 1 | 1 | 129 |
| | 4.2. Is the sample representative of the target population? | 126 | 1 | 2 | 129 |
| | 4.3. Are the measurements appropriate? | 127 | 1 | 1 | 129 |
| | 4.4. Is the risk of nonresponse bias low? | 70 | 24 | 35 | 129 |
| | 4.5. Is the statistical analysis appropriate to answer the research question? | 125 | 1 | 3 | 129 |
| MIXED METHODS STUDIES | 5.1. Is there an adequate rationale for using a mixed-methods design to address the research question? | 1 | 0 | 0 | 1 |
| | 5.2. Are the different components of the study effectively integrated to answer the research question? | 0 | 1 | 0 | 1 |
| | 5.3. Are the outputs of the integration of qualitative and quantitative components adequately interpreted? | 1 | 0 | 0 | 1 |
| | 5.4. Are divergences and inconsistencies between quantitative and qualitative results adequately addressed? | 0 | 1 | 0 | 1 |
| | 5.5. Do the different components of the study adhere to the quality criteria of each tradition of the methods involved? | 0 | 0 | 1 | 1 |

with a single study were Cote d’Ivoire (128), Democratic Republic of Congo (99), Mali (85), Swaziland (76), Tanzania (49), and The Gambia (30). We found no studies in the following SSA countries: Angola, Benin, Burundi, Cape Verde, Comoros, Equatorial Guinea, Gabon, Guinea, Guinea-Bissau, Lesotho, Liberia, Madagascar, Mauritania, Mauritius, Namibia, Niger, Sao Tome, Seychelles, Sierra Leone, Somalia, and Togo (Figure 4).

FIGURE 4 | Map showing spatial distribution of studies on breast, cervical and prostate cancer in Sub-Saharan Africa (global and multi-country studies were not included on the map).

FIGURE 5 | Figure showing the distribution of studies on breast, cervical and prostate cancer in Sub-Saharan Africa (some studies included more than one type of cancer).

Types of Cancer
The majority of the studies were on cervical cancer ($n = 93$, 67.4%), followed by breast cancer (67, 48.6%) and the least were on prostate cancer (48, 34.8%); some studies investigated all the three types of cancer ($n = 29$) while some reported two of the three cancers ($n = 15$) (Figure 5).

Burden of Cancer
Cervical Cancer
Prevalence Studies
A total of 51 studies reported the prevalence of cervical cancer in Sub-Saharan Africa, of which the majority ($n = 9$, 17.6%) were from Nigeria (28, 34, 45, 54, 64, 92, 93, 113, 137); these were retrospective record reviews of registries and patient files and two were cross-sectional studies (113, 137). This was followed
by six studies from Malawi: one cross-sectional study (118), one cross-sectional study of the Malawi Cancer Registry (133), two retrospective cohort studies (66, 68) and two retrospective record reviews of registries (53, 67). There were four studies from South Africa: a cross-sectional study (105), a retrospective cohort study (55), and two retrospective record reviews; registry (91) and patient files (65). There were also four studies from Uganda, which were retrospective record reviews of registries (59, 79, 94) and pathology reports (95). There were also three studies from Kenya: one cross-sectional study (132) and two retrospective record reviews of patient files (70) and registry (96). Another three studies were from Zambia: two cross-sectional studies (102, 126) and one retrospective record review of patient files (77). There were also three studies from Ethiopia: two cross-sectional studies (112, 146) and one retrospective review of patient files (51). There were two studies from Cameroon; both retrospective record reviews of patient files (41) and registry (73). One cross-sectional study was conducted in each of the following countries: Côte d’Ivoire (128), the Democratic Republic of Congo (99), Ghana (111), Rwanda (130), and Senegal (147). There was also one retrospective record review of patient files from Botswana (47) and another retrospective record review of smears from Swaziland (now called Eswatini) (76).

Six studies were African multi-country studies: two African studies; one cross-sectional study of Global Cancer Incidence, Mortality and Prevalence (GLOBOCAN), an online database providing global cancer statistics and estimates of incidence and mortality in 185 countries for 36 types of cancer, and all cancer sites combined (138) and a scoping review study (154), one cross-sectional study from South Africa and Uganda (120), and three systematic reviews [one from SSA (151), one from seven African countries (152) and one from Southern and Eastern Africa (153)]. There were three GLOBOCAN studies (104, 127, 145).

Incidence Studies
A total of 36 studies looked at the incidence of cervical cancer in Sub-Saharan Africa, of which the majority were from South Africa: two retrospective reviews of registries (10, 83), two retrospective cohort studies (81, 82), one retrospective record review of pathology reports (86) and one cross-sectional study (135). There were five studies from Uganda consisting of three record reviews of registries (35, 59, 74), one retrospective cohort study (40), and one retrospective record review of pathology reports (78). Three retrospective record reviews of registries were from Malawi (37, 52, 67). Two studies were retrospective record reviews of registries from Nigeria (24, 75). Two retrospective record reviews of registries from Zimbabwe (38, 39). Two Ethiopian retrospective record reviews of patient files (51) and registry (63) and two retrospective record reviews from Mozambique; one using pathology reports (57) and the other registry data (58).

There were five African multi-country studies: one systematic review including seven African countries (152) and four SSA studies; three cross-sectional studies (140, 141, 149) and one retrospective review of registry (6). There were five global studies, of which two were cross-sectional GLOBOCAN studies (109, 121), one cross-sectional study of Global Burden of Disease Study (117), a retrospective record review of registry (27), and a modeling study (158).

There was one study from each of the following countries: one retrospective record review of registry from The Gambia (30), one retrospective review of pathology reports from Eritrea (61), Ghana (71) and Sudan (84).

Other Burden Measures
A total of 11 studies considered other measures of cervical cancer burden; five studies reported mortality globally including Africa (117, 144), South Africa (129), Kenya (139) and Ethiopia (97). One cross-sectional study reported the population attributable fraction in a GLOBOCAN study (108). Two cross-sectional studies reported the disability-adjusted life years (DALYs) in Kenya (115) and for the SSA region (119). One GLOBOCAN study reported years of life lost (YLL) (148). Two cross-sectional studies in South Africa reported odds ratios for cervical cancer comparing HIV infected with HIV uninfected individuals (42, 110).

Breast Cancer
Prevalence Studies
A total of 32 studies reported the prevalence of breast cancer in Sub-Saharan Africa. Five studies were from Nigeria, of which four were retrospective record reviews of registries (28, 45, 64, 72) and one was a cross-sectional study (116). Four studies were from Ethiopia, three cross-sectional studies (101, 107, 146) and one retrospective review of patient files (51). Three studies were from Malawi, where one was a retrospective review of the registry (53) and two were retrospective cohort studies (66, 68). There were three studies from Uganda, two were retrospective record reviews of pathology reports (90, 95) and one was a retrospective record review of registry (59). Two studies were from South Africa, one retrospective record review (26) and a cross-sectional study of Demographic and Health Survey (DHS) data (125). Two studies were from Ghana, of which one was a cross-sectional study (134) and the other a retrospective record review of patient files (50). There was one study from each of the following countries: a retrospective record review of pathology reports from the Central African Republic (32), another retrospective record review of non-governmental records in Botswana (43), one cross-sectional study from Sudan (114), one cross-sectional study in both South Africa and Uganda (120), one retrospective record review of registry from Kenya (96), and a retrospective record review of pathology reports in Zambia (44).

There were two studies covering the whole of Africa, one a scoping review (154) and the other a GLOBOCAN cross-sectional study (138). There were also two GLOBOCAN cross-sectional studies (104, 145).

Incidence Studies
There were 28 studies reporting the incidence of breast cancer in Sub-Saharan Africa. Ten of the studies were covering the whole of Africa or SSA; a systematic review (2), three cross-sectional GLOBOCAN studies (122, 131, 143), three cross-sectional studies of the WHO database (106), Global Burden of Disease Study (117) and registries (141), two retrospective record review of
registries (87, 117) and a retrospective cohort study (69). In South Africa, there were three incidence studies on breast cancer; two retrospective record reviews of registries (89) and mammograms (98) and a cross-sectional study of the Statistics South Africa registry (135). There were also three studies from Uganda; one retrospective cohort study (40), and retrospective record review of registry (35) and pathology reports (78).

There were two Ethiopian studies on the incidence of breast cancer; one prospective observational study (157) and a retrospective record review of a registry (63). Also, two incidence studies in Mozambique consisted of a retrospective record review of pathology reports (57) and registry (58).

There was one incidence study from each of the following countries: a retrospective record review of registry in Nigeria (24), The Gambia (30), the Central African Republic (31), Eritrea (62), Malawi (37), Zimbabwe (38), Mali (85), and Sudan (84).

Other Burden Measures
A total of 12 studies considered other measures of breast cancer burden; mortality was measured by nine studies (46, 48, 69, 98, 117, 129, 139, 143, 144). DALYs were reported by four incidence studies (46, 69, 117, 119). One study reported quality of life (156) and another reported economic burden (142).

Prostate Cancer
Prevalence Studies
A total of 23 studies reported the prevalence of prostate cancer in Sub-Saharan Africa, of which seven were from Nigeria (25, 28, 45, 64, 103, 116, 124), three from Malawi (67, 118, 133); consisting mainly of retrospective record review of patient files and registries as well as cross-sectional studies (116, 124). The two prevalence studies from Ghana consisted of a cross-sectional study (123) and a review (155). There was one study from each of the following countries: a retrospective record review of registry from Kenya (96), Uganda (59), a cross-sectional study from Cameroon (100), a retrospective record review of pathology reports from South Africa (80) and Zambia (44), a retrospective cohort study from Tanzania (49), a cross-sectional study from Rwanda (136). The two studies that reported on the whole of Africa (138, 154) and two global studies including Africa (104, 145).

Incidence Studies
A total of 17 studies focused on the incidence of prostate cancer in Sub-Saharan Africa. There was one systematic review covering the entire African region (150). There were two global studies (46, 117) and two SSA studies (87, 141). There were two retrospective record reviews of pathology reports (57) and registry (58) from Mozambique. There were also two retrospective record reviews from South Africa (36, 88) and Uganda (35, 78). There was one retrospective record review of pathology reports from Eritrea (60), Ethiopia (63), Malawi (37), one retrospective record review of patient files in Nigeria (29), one retrospective record review of registries from The Gambia (30) and Zimbabwe (38).

Other Burden Measures
A total of eight studies considered other measures of prostate cancer burden; mortality was measured by seven studies (33, 46, 117, 129, 135, 139, 144). DALYs were reported by three incidence studies (46, 117, 119). One study reported years of life lost (YLL) (135).

DISCUSSION
The objective of this scoping review was to map the evidence on the burden of the three most common cancers in Sub-Saharan Africa, namely cervical, breast and prostate cancers. We comprehensively searched PubMed, Web of Science and Scopus databases, and included 138 studies: 93 on cervical cancer, 67 on breast cancer, and 48 on prostate cancer. This shows a disproportion in the distribution of cancer studies in SSA. Cervical and breast cancer receive more funding compared to prostate cancer, as they form sexual and reproductive health (SRH). Although breast cancer is the commonest cancer in SSA and globally (145), there are more studies on cervical cancer in the region. This could be because cervical cancer has been historically identified as AIDS-defining cancer (159), making cervical cancer screening a priority for women living with HIV. Poor resourced SSA countries have utilized the well-established HIV care platforms to screen for cervical cancer and donor funds have supported cervical cancer prevention and treatment programs in the region compared to breast cancer. While cervical cancer prevention HPV vaccines are widely available even in SSA, vaccinations against breast cancer are not yet available (160).

Majority of studies were done in South Africa and Nigeria. We identified some countries where there was no study on any of the three cancers. One of the reasons for this unavailability of cancer studies in some SSA countries could be because countries in SSA differ in terms of cancer control, with some countries putting in more resources than others. It has been reported that the cancer burden reported for SSA might be underestimated due to lack of appropriate screening, and diagnosis, poor access to treatment and care, and limitations in the technical workforce and infrastructure (14, 161). State-of-the-art cancer treatment and care, which includes cancer diagnostic equipment, is expensive, and since most countries in SSA are developing, they may not be able to acquire such equipment (162, 163). Additionally, the quality of the cancer data systems is poor, hence the possibility of having scarce research data in some of the SSA countries (164).

Most of the included studies were retrospective record review studies of mainly registries and patient files ($n = 77$), followed by cross-sectional studies ($n = 51$), in addition to some systematic reviews and prospective studies. The trend is similar elsewhere because cancer is a chronic condition which takes a while to detect; hence, most studies are done on existing data. Cross-sectional studies are also easier to perform since they involve cancer screening and surveillance activities that may be easily available at a public healthcare facility. There was only one study that included modeling and a few prospective studies were identified in this study. This shows that there is still a gap in research that employs modeling of the burden of prostate, cervical and breast cancer in SSA using prospective and statistical modeling. The main advantage of using modeling is that you
estimate DALYs and the results can be standardized by age group, making it easier for interpretation. The benefits of using prospective studies include reporting of quality of life of the patients and assessing time-to events like mortality. These studies allow one to report results beyond prevalence and incidences and the risk of occurrence of an outcome of interest can be estimated, which is more informative than the prevalence estimate.

Majority of studies reported prevalence and incidence of the cancers, but we also found studies reporting mortality, DALYs, and YLL. The quality of studies was overall satisfactory. We also identified a gap in the literature on these three types of cancer in SSA. Firstly, there were countries with no specific study on any of these three types of cancer. Secondly, we found few nationwide population-based surveys of these cancers to determine their true prevalence since most studies reported the proportion of each of the cancers from oncology records where the target population were only cancer patients. Multi-country studies were relatively few in this study. To understand more about the regional picture of prostate, cervical and breast cancer in SSA, multi-country studies are more preferred as these studies show the heavily burdened countries across the region and those that are performing well. This comparison allows key stakeholders to share information and knowledge across the SSA region. Moreover, national surveys on cancer are important for monitoring and surveillance of non-communicable diseases like cancer indicators, to inform policy. The reduction in the burden of breast, prostate and cervical cancers in SSA starts with the implementation of efforts within each country; hence, nationwide studies are important and these can feed into multi-country studies.

To our knowledge, this is the first scoping review on the burden of cervical, breast and prostate cancers in SSA. There is a published scoping review (165) that mapped evidence on the prevalence, incidence, mortality and trends of HPV-associated cancers in SSA, which only found eight studies (six reviews and two quantitative studies). Another systematic review investigated only the incidence of prostate cancer in Africa (150). Our scoping review is different because we investigated the three most common cancers in SSA, namely the breast, cervical and prostate cancers. However, our conclusions in identifying gaps in effective cancer registry systems in Africa are similar to the previously published reviews.

We used a very experienced librarian who is also part of the co-authors to perform a comprehensive search in three main electronic databases. The search strategy used medical subject headings (MeSH) terms and was not limited in language or date; we searched all studies from inception to the current search date. Pairs of co-authors performed each of the processes, including screening of studies, data extraction, and charting, repeatedly. We used EndNote 20 software to manage the references and used the Rayyan software in screening the studies.

**Study Limitations**

However, this study has some limitations. The main limitation is that we only searched three electronic databases and did not search the grey literature such as theses and dissertations of universities. We excluded some studies that did not report the cancer burden indicators defined in this scoping review. Nonetheless, since we identified 138 studies, it is more likely that these included studies are representative of the trends and patterns in the burden of cervical, breast and prostate cancer studies in SSA.

**CONCLUSIONS AND RECOMMENDATIONS**

We have identified a lack of comprehensive studies quantifying the burden of cervical, breast, and prostate cancers in SSA. This is crucial to help policy makers to decide on appropriate policies. Other countries in SSA do not have a single study on any of these three main cancers, thereby reflecting a great need for setting up research priorities, including funding frameworks for such essential studies. We recommend that countries in SSA expand their national surveys to include measures of cancer burden – more specifically the burden of cervical, breast and prostate cancers. Our scoping review enriched the pool of knowledge and provided a deeper understanding of the burden (incidence, prevalence, and DALYs) of cervical, breast, and prostate cancers in SSA, which could inform the public health systems’ decision-making. Policy responses to the growing burden of cancer in general and more specifically that of cervical, breast, and prostate cancers will be required in less developed countries such as those in SSA to mitigate the threat caused by these cancers. This scoping review provided useful, relevant, timely and easily accessible information on the burden of the three cancers to facilitate the efforts by policymakers to decisively ramp up prevention and treatment interventions. These results can also help set research priorities for future cancer burden studies as well as help identify opportunities to improve existing policy frameworks around cancer prevention and treatment, especially for cervical, breast and prostate cancers in SSA.

**AUTHOR CONTRIBUTIONS**

AM conceptualized the topic with assistance from MMoy, MMoh, ZM-Z, HT, JB, GS, KK, NM, PN, PS, TE, and IM who contributed equally to the writing, research, critical review and proofreading of the manuscript. KK performed the search with assistance from MMoy and TE. All authors contributed to the article and approved the submitted version.

**FUNDING**

This research was funded in part by the National Science Foundation, grant number 134651, to the MASAMU Advanced Study Institute.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2022.908302/full#supplementary-material
REFERENCES

1. Bray F, Soerjomataram I. The changing global burden of cancer: transitions in human development and implications for cancer prevention and control. *Cancer*. (2015) 2:32–44. doi: 10.1007/s10582-014-4648-3
2. Anorlu RI. Cervical cancer: the sub-Saharan African perspective. *Reprod Health Matters*. (2008) 16:41–9. doi: 10.1016/S0968-8080(08)32415-X
3. Popat EJ, O'Malley L. Scoping studies: towards a methodological framework. *J Res Soc Methods*. (2015) 2:110–8. doi: 10.1007/s10909-015-9363-9
4. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *Int J Soc Res Methodol*. (2013) 16:123–48. doi: 10.1177/1364557313481636
5. Sankaranarayanan R, Budukh AM, Rajkumar R. Effective screening and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. (2015) 136:E359–86. doi: 10.1002/ijc.29210
6. Jed-Agba E, Joko WY, Liu B, Buziba NG, Borok MZ, Korir A, et al. Trends in cervical cancer incidence in sub-Saharan Africa. *Br J Cancer*. (2020) 123:148–54. doi: 10.1038/s41416-020-0831-9
7. World agency for research on cancer (IARC). Cancer Tomorrow, WHO, 2018.
8. Lott BE, Trejo MJ, Baum C, McClelland DJ, Adsul P, Madhivanan P, et al. Interventions to increase uptake of cervical screening in sub-Saharan Africa: a scoping review using the integrated behavioral model. *BMC Public Health*. (2020) 20:1–18. doi: 10.1186/s12889-020-08777-4
9. Ntekim A. Cervical cancer in sub-Saharan Africa. *Topics Cancer Advoc*. (2012) 4:45–9. doi: 10.5772/27200
10. Somydila NM, Bradshaw D, Dhansay MA, Stefan DC. Increasing Cervical Cancer Incidence in Rural Eastern Cape Province of South Africa From 1998 to 2012: A Population-Based Cancer Registry Study. *JGO Glob Oncol*. (2020) 6:1–8. doi: 10.1002/jgog.00198
11. Sankaranarayanan R, Budukh AM, Rajkumar R. Effective screening programmes for cervical cancer in low- and middle-income developing countries. *Bull World Health Organ*. (2001) 79:954–62
12. Habila MA, Mantina N, Kimaru LJ, Musa J, Ingram M, Sagay A. Community engaged approaches to cervical cancer prevention and control in sub-saharan Africa: a scoping review protocol. *Front Glob Women’s Health*. (2021) 2.
13. Arbyn M, Weiderpass E, Bruni L, Sadeghi-Nichii M, Parkin DM. HPV and its relation with cervical cancer. *Adv Cancer Res*. (2011) 108:15–20. doi: 10.1016/B978-0-12-386268-9.00004-4
14. Cassim N, Ahmad A, Wadee R, Rebbeck TR, Glencross DK, George JA. Pattern of primary gynecological malignancies in a tertiary hospital in the Central African Republic. *J Nephrol Urol Res*. (2018) 15:e0229854. doi: 10.1371/journal.pone.0229854
15. Briggs ND, Kaye CH. Pattern of primary gynecological malignancies as seen in a tertiary hospital situated in the Rivers State of Nigeria. *Int J Gynaecol Obstet*. (1990) 31:157–61. doi: 10.1016/0020-7292(90)90714-V
16. Bokolo CE, Yin P, Bekolo CE, Pamatika CM, Djeintote M, et al. Malignant tumours of the breast in Cameroon. *J Natl Med Assoc*. (2006) 98:539–43. doi: 10.1186/s13027-019-0228-7
17. Hong Q, Pluye P, Fabregues S, Bartlett G, Boardman F, Cargo M, et al. Mixed Methods Appraisal Tool (MMAT) Version 2018: User Guide. Registration of Copyright 1148552 (2018) 34:285–91
18. Arbyn M, Castellsagué X, Saraiya M, Ferlay J, Parkin DM, et al. Cancer burden among HIV-positive persons in Nigeria: preliminary findings from the Nigerian AIDS-cancer-1000 study match. *AIDS*. (2014) 9:1. doi: 10.1097/01.AIDS.2937-9:1
19. Anunobi CC, Akinde OR, Elesha SO, Daramola AO, Tijani KH, Ojewola RW. Prostate diseases in Lagos, Nigeria: a histologic study with iPSA correlation. *Niger Postgrad Med J*. (2011) 18:98–104.
20. Apfelstaedt JP, Dalmayer L, Baetjes K. Mammographic screening for breast cancer in a resource受限 environment. *South Afr J Med*. (2014) 104:294–6. doi: 10.1016/S0298-7412
21. Arbyn M, Castellsagué X, Sanjose Sde, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. *Ann Oncol*. (2011) 22:2675–86. doi: 10.1093/annonc/mdr015
22. Adewole O, Adeyemo AA, Adewole DF, Fayankinnu VB, Dolapo DC. Cancer distribution pattern in south-western Nigeria. *Tanzan J Health Res*. (2011) 13:125–31. doi: 10.4314/thr.v13i2.5226
23. Badmus TA, Adesunjami AR, Yusuf BM, Oseni GO, Ezizi AK, Bakare TI, et al. Burden of prostate cancer in southwestern Nigeria. *Urology*. (2010) 76:412–6. doi: 10.1016/j.urology.2010.03.020
24. Bah E, Parkin DM, Hall AJ, Jack AD, Whittle H. Cancer in the Gambia: 1988-97. *Br J Cancer*. (2001) 84:1207–14. doi: 10.1054/bjc.2001.1730
25. Balekouzou A, Yin P, Bekolo CE, Pamatika CM, Djeintote M, et al. Histo-epidemiological profile of breast cancers among women in the Central African Republic: about 174 cases. *Breast Cancer*. (2018) 18:387. doi: 10.1186/s12885-018-4526-2
26. Balekouzou A, Yin P, Pamatika CM, Bishwajit G, Nambewa SW, et al. Epidemiology of breast cancer: retrospective study in the Central African Republic. *BMC Public Health*. (2016) 16:1230. doi: 10.1186/s12889-016-3863-6
27. Bekisia J, Getinet T, Tanie S, Dribi J, Hassen HY. Survival and prognostic determinants of prostate cancer patients in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: a retrospective cohort study. *PLoS ONE*. (2020) 15:e0229854. doi: 10.1371/journal.pone.0229854
28. Ntekim A, Akinde OR, Elesha SO, Daramola AO, Tijani KH, Ojewola RW. Prostate diseases in Lagos, Nigeria: a histologic study with iPSA correlation. *Niger Postgrad Med J*. (2011) 18:98–104. doi: 10.1186/s13027-019-0228-7
52. Horner MJ, Chasimpha S, Spoerri A, Edwards J, Bohlius J, Tweya H, Gunda A, Kido I, Kilonzo S, Nkandala I, Igenge J, Mpondo B. Prevalence and Associated Factors of Incidentally Diagnosed Prostatic Carcinoma among Patients Who Had Transurethral Prostatectomy in Tanzania: A Retrospective Study. *Ethio J Health Sci.* (2018) 28:11–8. doi: 10.4314/ehs.v28i1.3

55. Katz IT, Butler LM, Crankshaw TL, Wright AA, Bramhill K, Leone DA, et al. The Global Burden of Cancer 2013 Global Epidemiological Trends in Cancer Incidence in Maputo, Mozambique, 1991–2008. *PLoS ONE.* (2016) 11:e015472. doi: 10.1371/journal.pone.015472

62. Medhin LB, Mackenzie K, Oswe Y, Mazingira P, Manyangana P, Nkatha S, et al. Risk factors for common cancers among patients at Kamuzu Central Hospital in Lilongwe, Malawi: a retrospective cohort study. *J Glob Oncol.* (2018) 4:1–11. doi: 10.1002/jgo.25168

65. Mohammed AZ, Edino ST, Ochicha O, Gwarzo AK, Samaila AA. Cancer in Nigeria: a 10-year analysis of the Kano cancer registry. *Niger J Med.* (2008) 17:280–4. doi: 10.4314/njm.v17i3.3796

66. Mubarak S, Yu Y, Wang F, Malik SS, Liu X, Fawad M, et al. Epidemiological and sociodemographic transitions of female breast cancer incidence, death, case fatality and DALYs in 21 world regions and globally, from 1990 to 2017: An Age-Period-Cohort Analysis. *J Adv. Res.* (2021) 7178–96. doi: 10.1016/j.jare.2021.07.012

67. Msyamboza KP, Dzamalala C, Mdokwe C, Kamiza S, Lemerani M, Dzowela T, et al. The Burden of Cancer in Malawi: common types, incidence and trends: national population-based cancer registry. *BMC Res Notes.* (2012) 5:149. doi: 10.1186/1756-0500-5-149

68. Msyamboza KP, Manda G, Tembo B, Rambvo A, Chiteze L, Mbindura C, et al. Cancer survival in Malawi: a retrospective cohort study. *Pan Afr Med J.* (2019) 14:239. doi: 10.11604/pamj.2014.19.234.4675

69. Nkusu NC, Cumber SN, Williams T, Anchang-Kimbi JK, Yankam BM, et al. Reduction in prevalence of invasive cervical cancer in the Greater Accra and Ashanti Regions of Ghana. *J Glob Oncol.* (2017) 3:782–90. doi: 10.1002/jgo.2016.005744

70. Ogundele OA, Adeyemo LA. Trends in cancer incidence in Swaziland, Southern Africa: a descriptive study. *Clin Infect Dis.* (2021) 73:1778–86. doi: 10.1093/cid/ciab178

71. Odida M, Schmauz R, Lwanga SK. Grade of malignancy of cervical cancer at a referral hospital in Malawi. *Int J Cancer.* (2019) 9:737–41. doi: 10.1002/ijc.10384

72. Odima M, Schmauz R, Iwanga SK. Grade of malignancy of cervical cancer in regions of Uganda with varying malarial endemicity. *Int J Cancer.* (2002) 99:737–41. doi: 10.1002/jic.10384

73. Okotteme SM, Katareja E, Wabinga H, Parkin DM. Cancer survival in Malawi: a retrospective cohort study. *Pan Afr Med J.* (2015) 19:234. doi: 10.11604/pamj.2014.19.234.4675

74. Odida M, Schmauz R, Lwanga SK. Grade of malignancy of cervical cancer in regions of Uganda with varying malarial endemicity. *Int J Cancer.* (2002) 99:737–41. doi: 10.1002/jic.10384

75. Odumutu CO, Alabi OA, Ohiara MS, Abayoha MO, Oyebamiji T, et al. Cancer presentation patterns in Lagos, Nigeria: a descriptive study. *J Glob Oncol.* (2018) 2:375–80. doi: 10.1002/jgo.2015.002469

76. Oyebamiji T, et al. Cancer presentation patterns in Lagos, Nigeria: a descriptive study. *J Glob Oncol.* (2018) 2:375–80. doi: 10.1002/jgo.2015.002469

77. Parkin DM, Wabinga H, Nambooze S, Wabwire-Mangen F. AIDS-related Incidence and Mortality of Breast Cancer in Uganda, 1991–2006. *J Clin Oncol.* (2008) 26:e1428–6. doi: 10.1200/JCO.2007.14.1668

78. Parkin DM, Nambooze S, Wabwire-Mangen F, Wabinga HR. Changing cancer incidence in Kampala, Uganda, 1991-2006. *Int J Cancer.* (2010) 126:1187–95. doi: 10.1002/jic.21433
119. Gouda HN, Charlson F, Sorsdahl K, Ahmadzada S, Ferrari AJ, Erskine H, et al. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Global Health. (2021) 8:e1027–37. doi: 10.1016/j.lghc.2021.10.075

120. Lal Ruche A, Ramon R, Mensah-Ado I, Bergeron C, Diomande M, Syslla-Kamano S, et al. Burden of non-communicable diseases in sub-Saharan Africa, 1990–2019: results from the Global Burden of Disease Study 2017. Lancet Glob Health. (2019) 7:e1375–87. doi: 10.1016/S2214-109X(19)30374-2

121. He WQ, Li C. Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends. Gynecol Oncol. (2021) 163:583–92. doi: 10.1016/j.ygyno.2021.10.075

122. Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benedita I, et al. The prevalence and burden of symptoms amongst cancer patients attending palliative care in two African countries. Eur J Cancer. (2011) 47:51–6. doi: 10.1016/j.ejca.2010.08.003

123. Hee QW, Li C. Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends. Gynecol Oncol. (2021) 163:583–92. doi: 10.1016/j.ygyno.2021.10.075

124. Li Q, Li C. Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends. Gynecol Oncol. (2021) 163:583–92. doi: 10.1016/j.ygyno.2021.10.075

125. Hsing AW, Yeboah E, Biritwum R, Tettey Y, Marzo AMD, Adjei A, et al. Burden of non-communicable diseases in sub-Saharan Africa, 1990–2019: results from the Global Burden of Disease Study 2017. Lancet Glob Health. (2019) 7:e1375–87. doi: 10.1016/S2214-109X(19)30374-2

126. Kapambwe S, Sahasrabuddhe VV, Blevins M, Mwanahamuntu MH, Mudenda V, Shepherd BE, et al. Age Distribution and Determinants of Palliative care in two African countries. Eur J Cancer. (2019) 106:477–84. doi: 10.1016/j.ejca.2019.04.017

127. Khalil AI, Mpunga T, Wei FX, Baussano I, de Martel C, Bray F, et al. Age-specific burden of cervical cancer associated with HIV: a global analysis for the Global Burden of Disease Study. Int J Cancer. (2019) 144:49–58. doi: 10.1002/ijc.31664

128. Kim PM, Bray F, Ferlay J, Jemal A. Cancer in Africa 2012. Cancer Epidemiol Biomark Prev. (2014) 23:953–66. doi: 10.1158/1055-9965.EPI-14-0281

129. Kim PP, Howard PA, Laserson KE, Asemak N, BinyeCM, Anglo SY, Khagayi C, et al. Deaths Attributed to Non-Communicable Diseases among Rural Kenyan Adults Are Proportionately Increasing: Evidence from a Health and Demographic Surveillance System, 2003-2010. PLoS ONE. (2014) 9:e114010. doi: 10.1371/journal.pone.0114010

130. Kim PM, Bray F, Ferlay J, Jemal A. Cancer in Africa 2012. Cancer Epidemiol Biomark Prev. (2014) 23:953–66. doi: 10.1158/1055-9965.EPI-14-0281

131. Kim PM, Bray F, Ferlay J, Jemal A. Cancer in Africa 2012. Cancer Epidemiol Biomark Prev. (2014) 23:953–66. doi: 10.1158/1055-9965.EPI-14-0281

132. Memiah P, Makokha V, Mbuthia W, Kiiru GW, Agbor S, Odhiambo F, et al. Global burden of cervical cancer in Africa, 2012 and 2035: a population-based study. Int J Cancer. (2019) 144:1824–33. doi: 10.1002/ijc.31880

133. Mukhula V, Sibale D, Tarmahomed L, Dzamalala C, Msyamboza K, Chasimpha S. Characterising cancer burden and quality of care at two palliative care clinical centers in Malawi. Malawi Med J. (2017) 29:130–5. doi: 10.4334/mmj.v29i2.10

134. Muhindo C, Nyabubale A, Eliason S, Mohammed Adamu S, Debrab N. Pattern of Breast Cancer Distribution in Ghana: A Survey to Enhance Early Detection, Diagnosis, and Treatment. Int J Breast Cancer. (2016) 2016:3645308. doi: 10.1155/2016/3645308

135. Mujumbi JK, Sebata D, Caraballo L, Njau T, Akaveni S, Tarmahomed L, et al. Patterns of Cancer Burden in SSA. Mapping Cancer Burden in SSA.
153. Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, et al. Estimates of the global burden of cervical cancer associated with HIV. *Lancet Glob Health.* (2021) 9:e161–9. doi: 10.1016/S2214-109X(20)30459-9

154. Parkin DM, Sitas F, Chirenje M, Stein L, Abratt R, Wabinga H. Part I: Cancer in indigenous Africans-Burden, distribution, and trends. *Lancet Oncol.* (2008) 9:683–92. doi: 10.1016/S1470-2045(08)70175-X

155. E.D. Yeboah. Prevalence of benign prostatic hyperplasia and prostate cancer in Africans and Africans in the diaspora. *J West Afr Coll Surg.* (2016) 6:1–30.

156. Dano D, Hénon C, Sarr O, K, Ba M, Badiane A, et al. Quality of Life During Chemotherapy for Breast Cancer in a West African Population in Dakar, Senegal: A Prospective Study. *J Glob Oncol.* (2019) 5:1–9. doi: 10.1200/JGO.19.00106

157. Eber-Schulz P, Tariku W, Reibold C, Addissie A, Wickenhauser C, Fathke C, et al. Survival of breast cancer patients in rural Ethiopia. *Breast Cancer Res Treat.* (2018) 170:111–8. doi: 10.1007/s10549-018-4724-z

158. Coates MM, Kintu A, Gupta N, Wroe EB, Adler AJ, Kwan GF, et al. Burden of non-communicable diseases from infectious causes in 2017: a modelling study. *Lancet Glob Health.* (2020) 8:e1489–98. doi: 10.1016/S2214-109X(20)30358-2

159. Finocchario-Kessler S, Wexler C, Maleba M, Mabachi N, Ndikum-Moffor F, Bukusi E. Cervical cancer prevention and treatment research in Africa: a systematic review from a public health perspective. *BMC Womens Health.* (2016) 16:29. doi: 10.1186/s12905-016-0306-6

160. Zachariah NN, Basu A, Gautam N, Ramamoorthi G, Kodumudi KN, Kumar NB, et al. Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination. *Front Immunol.* (2021) 12:4864. doi: 10.3389/fimmu.2021.786286

161. Odedina FT, Akinremi TO, Chingwundoh F, Roberts R, Yu D, Reams RR, et al. Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. *Infect Agent Cancer.* (2009) 4:1–8. doi: 10.1186/1750-9378-4-S1-S2

162. Ukoli F, Osime U, Akereyeni F, Okunzuwa O, Kittles R, Adams-Campbell L. Prevalence of elevated serum prostate-specific antigen in rural Nigeria. *Int J Urol.* (2003) 10:315–22. doi: 10.1046/j.1442-2042.2003.00633.x

163. Hamdi Y. Abdeljaoued-Tej I, Zatchi AA, Abdelhak S, Boubaker S, Brown JS, et al. Cancer in Africa: The Untold Story. *Front Oncol.* (2021) 11:650117. doi: 10.3389/fonc.2021.650117

164. Ogumibiyi JO, Shittu OB. Increased incidence of prostate cancer in Nigerians. *J Natl Med Assoc.* (1999) 91:159–64.

165. Lekoane KMB, Kuupiel D, Mashamba-Thompson TP, Ginindza TG. Evidence on the prevalence, incidence, mortality and trends of human papilloma virus-associated cancers in sub-Saharan Africa: systematic scoping review. *BMC Cancer.* (2019) 19:563. doi: 10.1186/s12885-019-5781-3

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Musekiwa, Moyo, Mohammed, Matsena-Zingoni, Twabi, Batidzirai, Singini, Kgarosi, Mchunu, Nevhungoni, Silinda, Ekwonodu and Maposa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.